Yuko Kawano-Tsuchiya

Kitakyushu, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study.

Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study.

Journal: Translational lung cancer research

Published: February 20, 2026

Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102).

Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102).

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 06, 2025

Association of TP53 gain-of-function mutations with early osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma.

Association of TP53 gain-of-function mutations with early osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma.

Journal: ESMO open

Published: June 06, 2025

Platinum plus etoposide with durvalumab for extensive-stage small-cell lung cancer with untreated brain metastases: a multicenter, single-arm phase II trial (LOGiK2001, SPEED).

Platinum plus etoposide with durvalumab for extensive-stage small-cell lung cancer with untreated brain metastases: a multicenter, single-arm phase II trial (LOGiK2001, SPEED).

Journal: ESMO open

Published: March 03, 2025

Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study.

Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study.

Journal: Thoracic cancer

Published: February 28, 2025

IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer.

IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer.

Journal: Molecular cancer

Published: February 25, 2025

Suitability of Frozen Pleural Fluid Pellets for Next-Generation Sequencing-Based Driver Gene Testing in Non-Small Cell Lung Cancer.

Suitability of Frozen Pleural Fluid Pellets for Next-Generation Sequencing-Based Driver Gene Testing in Non-Small Cell Lung Cancer.

Journal: Thoracic cancer

Published: December 14, 2024

Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003).

Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003).

Journal: JTO clinical and research reports

Published: December 04, 2024

A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET).

A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET).

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 22, 2024

Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.

Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 19, 2024

Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004).

Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004).

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 15, 2024

Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.

Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.

Journal: Nature communications

Published: April 06, 2024

Showing 1-12 of 31

Last Updated: 09/26/2026